Evaluation of the synergistic adverse effects of concomitant therapy with statins and fibrates on rhabdomyolysis

被引:25
|
作者
Matzno, S
Tazuya-Murayama, K
Tanaka, H
Yasuda, S
Mishima, M
Uchida, T
Nakabayashi, T
Matsuyama, K
机构
[1] Mukogawa Womens Univ, Sch Pharmaceut Sci, Dept Biochem 1, Nishinomiya, Hyogo 6638179, Japan
[2] Daiichi Univ, Coll Pharmaceut Sci, Minami Ku, Fukuoka 8158511, Japan
关键词
D O I
10.1211/002235703765951401
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Rhabdomyolysis is a severe adverse effect of hypolipidaemic agents such as statins and fibrates. We evaluated this muscular cytotoxicity with an in-vitro culture system. Cellular apoptosis was determined using phase-contrast and fluorescein microscopic observation with Hoechst 33342 staining. L6 rat myoblasts were treated with various statins and bezafibrate under various conditions. With statins only, skeletal cytotoxicity was ranked as cerivastatin>fluvastatin>simvastatin>atorvastatin> pravastatin in order of decreasing potency. Combined application of fibrates enhanced atorvastatin-induced myopathy, which causes little apoptosis alone. These results suggest that statins and fibrates synergistically aggravate rhabdomyolysis.
引用
收藏
页码:795 / 802
页数:8
相关论文
共 50 条
  • [41] Systematic review and meta-analysis of Statins-Fibrates therapy in diabetic dyslipidemia patients
    Shuang Zheng
    Yang-Xue Li
    Ting-Ting Han
    Yao Zhang
    Dong-Dong Jiang
    Yao-Min Hu
    World Journal of Meta-Analysis, 2014, (04) : 194 - 203
  • [42] Cardiovascular disease with diabetes or the metabolic syndrome: should statins or fibrates be first line lipid therapy?
    Robins, SJ
    CURRENT OPINION IN LIPIDOLOGY, 2003, 14 (06) : 575 - 583
  • [43] Should statins or fibrates be first-line lipid therapy for those with diabetes or the metabolic syndrome?
    Holt, RIG
    DIABETES OBESITY & METABOLISM, 2004, 6 (03): : 235 - 235
  • [44] Effects of statins and/or fibrates on C-reactive protein and lipid levels in metabolic syndrome
    Reiber, I
    Mezö, I
    ATHEROSCLEROSIS SUPPLEMENTS, 2005, 6 (01) : 119 - 119
  • [45] Maximizing Benefits and Minimizing Adverse Effects of Statins
    Schade, David S.
    Blankenship, James
    Eaton, R. Philip
    ENDOCRINE PRACTICE, 2024, 30 (01) : 83 - 85
  • [47] Pharmacogenomics of statins: understanding susceptibility to adverse effects
    Kitzmiller, Joseph P.
    Mikulik, Eduard B.
    Dauki, Anees M.
    Murkherjee, Chandrama
    Luzum, Jasmine A.
    PHARMACOGENOMICS & PERSONALIZED MEDICINE, 2016, 9 : 97 - 106
  • [48] Adverse events with concomitant amiodarone and statin therapy
    Alsheikh-Ali, AA
    Karas, RH
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2005, 45 (03) : 382A - 382A
  • [49] Storms, tea cups and the adverse effects of statins
    Wierzbicki, A. S.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2009, 63 (09) : 1268 - 1270
  • [50] Adverse side effects of statins in the oral cavity
    Pascual Cruz, Montserrat
    Chimenos Kuestner, Eduardo
    Garcia Vicente, Jose Antonio
    Mezquiriz Ferrero, Xavier
    Borrell Thio, Eulalia
    Lopez Lopez, Jose
    MEDICINA ORAL PATOLOGIA ORAL Y CIRUGIA BUCAL, 2008, 13 (02): : E98 - E101